Prostate Cancer Medicine Market Witness a Pronounce Growth by 2025 | AMRPosted by Sandeep Salunkhe on March 25th, 2019 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system. This cancer develops slowly, with no early detectable symptoms for many years. The precise cause of prostate cancer is unknown; however, factors such as obesity, high calcium diet, lack of exercise, ethnicity (African American men), and old age contribute to its occurrence. Increase in geriatric population globally and rise in prevalence of prostate cancer due to hectic lifestyle, ethnicity, unhealthy diet, and lack of awareness are expected to fuel the market growth. According to the National Cancer Institute, in the U.S., prostate cancer is estimated to cause about 26,730 deaths in 2017. In addition, R&D activities in the field of prostate cancer drugs and emerging economies in developing countries are expected to present new opportunities during the forecast period. However, stringent government regulations, high cost of prostate cancer medicines and low awareness of prostate cancer restrict the growth. The prostate cancer medicine market is segmented on the basis of drug type and geography. Based on drug type, it is divided into hormonal therapy drugs, chemotherapy drugs, immunotherapy drugs, and target therapy drugs. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Key Benefits
Send Enquiry Us @ https://www.alliedmarketresearch.com/purchase-enquiry/2653 Like it? Share it!More by this author |